[1]王立凯,黄丽娟,潘学继,等.人附睾蛋白4单克隆抗体与免放试剂盒的制备及其对卵巢癌诊断的临床价值探讨[J].国际放射医学核医学杂志,2016,40(3):183-186,207.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
　Wang Likai,Huang Lijuan,Pan Xueji,et al.Preparation of monoclonal antibodies and immunoradiometric assay kit against human epididymis protein 4 and its clinical value in diagnosis of ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):183-186,207.[doi:10.3760/cma.j.issn.1673-4114.2016.03.005]
点击复制

人附睾蛋白4单克隆抗体与免放试剂盒的制备及其对卵巢癌诊断的临床价值探讨(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第3期
页码:
183-186,207
栏目:
出版日期:
2016-05-25

文章信息/Info

Title:
Preparation of monoclonal antibodies and immunoradiometric assay kit against human epididymis protein 4 and its clinical value in diagnosis of ovarian cancer
作者:
王立凯;  黄丽娟;  潘学继;  张续;  董全文
1. 300301, 天津市协和化学发光诊断试剂有限公司研发中心;
2. 300301, 天津市协和医药科技集团有限公司, 天津市免疫分析技术企业重点实验室
Author(s):
Wang Likai;  Huang Lijuan;  Pan Xueji;  Zhang Xu;  Dong Quanwen
1. Union CLIA Diagnostic Technology (Tianjin) Ltd., Tianjin 300301, China;
2. Key Lab of Immunoassay Technology for Tianjin’s Companies, Union Medical & Pharmaceutical Technology Group(Tianjin) Ltd., Tianjin 300301, China
关键词:
人附睾蛋白4; 卵巢肿瘤; 抗体; 单克隆; 免疫放射分析
Keywords:
Human epididymis protein-4; Ovarian neoplasm; antibodies Monoclonal; Immunoradiometric assay
DOI:
10.3760/cma.j.issn.1673-4114.2016.03.005
摘要:
目的 制备人附睾蛋白4(HE4)单克隆抗体并研制免放分析试剂盒,探讨其在卵巢癌临床诊断中的价值。方法 用重组人HE4免疫小鼠,通过细胞融合杂交瘤技术制备并筛选可以配对的HE4单抗,用125I标记其中一株单抗,研制HE4免放试剂盒,并评价其检测的灵敏度。通过检测临床血清标本来评价其对卵巢癌诊断的灵敏度和特异度。结果 筛选出了一对亲和力与特异性高的HE4单抗,其免放试剂盒检测的灵敏度为3.65 pmol/L,其对卵巢癌的临床诊断的灵敏度可达90.83%,特异度为99.17%。结论 制备的单克隆抗体亲和力高,研制的免放试剂盒各项指标较好,可用于卵巢癌的早期临床诊断和疗效观察,降低卵巢癌患者的病死率。
Abstract:
Objective To prepare monoclonal antibodies and immunoradiometric assay kit against human epididymis protein 4 (HE4) and study its clinical value in diagnosis of ovarian cancer. Methods BALB/c mice were immunized with recombinant HE4 antigen, 2 paired monoclonal antibodies were generated through splenic cell and myeloma cell fusion and screening. The detection antibody was labeled with 125 Iodine and immunoradiometric assay kit for HE4 was developed. The detect sensitivity of the kit was determined, and its clinical sensitivity and specificity in diagnosis of ovarian cancer was evaluated. Results Two paired monoclonal antibodies with high affinity and specialty were generated. The detect sensitivity of this immunoradiometric assay was 3.65 pmol/L, and the clinical sensitivity and specificity in diagnosis of ovarian cancer was 90.83% and 99.17% respectively. Conclusions This study was prepared by a high affinity monoclonal antibodies against HE4, and the technical indexes of HE4 immunoradiometric assay kit were rather good. So it could be used in early diagnosis and curative effect observation of ovarian cancer, and reduce its lethality rate.

参考文献/References:

[1] 国家食品药品监督管理局.肿瘤标志物类定量检测试剂注册申报资料指导原则[EB].2011-03-24,http://www.sda.gov.cn/WS01/CL0274/60448.html. China Food and Drug Administration.Guiding principles for registration of quantitative detecting kits of tumor markers[EB].2011-03-24,http://www.sda.gov.cn/WS01/CL0274/60448.html.
[2] 董丽, 昌晓红, 叶雪, 等.血清人附睾分泌蛋白4和CA125水平检测在卵巢癌中的诊断价值[J].中华妇产科杂志, 2008, 43(12):931-936.DOI:10.3321/j.issn:0529-567X.2008.12.013.Dong L, Chang XH, Ye X, et al.The values of serum human epididymis secretory protein 4 and CA125 assay in the diagnosis of ovarian malignancy[J].Chin J Obstet Gynecol, 2008, 43(12):931-936.
[3] Kirchhoff C, Habben I, Ivell R, et al.A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors[J].Biol Reprod, 1991, 45(2):350-357.
[4] 刘晓宇, 姜洁.血清肿瘤标志物人附睾蛋白4在卵巢癌诊断中的研究进展[J].肿瘤, 2010, 30(8):711-714.DOI:10.3781/j.issn.1000-7431.2010.08.015.Liu XY, Jiang J.Serum human epididymis protein 4 as a tumor marker in the diagnosis of ovarian cancer[J].Tumor, 2010, 30(8):711-714.
[5] 张卫云, 孙朝晖, 李薇, 等.人附睾蛋白4与血清CA125联合检测在卵巢癌诊断中的应用价值[J].生物技术通讯, 2013, 24(4):549-551.DOI:10.3969/j.issn.1009-0002.2013.04.025.Zhang WY, Sun ZH, Li W, et al.Diagnostic Value of Combined Detection of Human Epididymis Protein 4 with Serum CA125 in Ovarian Epithelial Cancer[J].Lett Biotech, 2013, 24(4):549-551.DOI:10.3969/j.issn.1009-0002.2013.04.025.
[6] Moore RG, McMeekin DS, Brown AK, et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J].Gynecol Oncol, 2009, 112(1):40-46.DOI:10.1016/j.ygyno.2008.08.031.
[7] 王慜杰, 齐军, 王海, 等.人附睾蛋白4与糖类抗原125联合检测在卵巢癌诊断中的应用价值[J].中华肿瘤杂志, 2011, 33(7):540-543.DOI:10.3760/cma.j.issn.0253-3766.2011.07.015.Wang MJ, Qi J, Wang H, et al.Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma[J].Chin J Oncol, 2011, 33(7):540-543.

相似文献/References:

[1]孙昱,符达,刘兴党.卵巢癌循环肿瘤细胞的生物学特性及其临床应用进展[J].国际放射医学核医学杂志,2016,40(1):60.[doi:10.3760/cma.j.issn.1673-4114.2016.01.012]
　Sun Yu,Fu Da,Liu Xingdang.Progress in biological characteristics and clinical application of circulating tumor cells in ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):60.[doi:10.3760/cma.j.issn.1673-4114.2016.01.012]
[2]宋梦姣,韩栋梁,葛宁,等.放疗增敏研究中人卵巢癌SKOV3乏氧细胞模型的建立方法[J].国际放射医学核医学杂志,2014,38(6):356.[doi:10.3760/cma.j.issn.1673-4114.2014.06.002]
　Song Meng-jiao,Han Dong-liang,Ge Ning,et al.The method of establishing the hypoxic SKOV3 cellular model in the research of radiotherapy sensitizer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):356.[doi:10.3760/cma.j.issn.1673-4114.2014.06.002]
[3]李鹏,赵卫威,杨建伟.18F-FDG PET-CT在探测卵巢癌术后复发与转移中的应用价值[J].国际放射医学核医学杂志,2012,36(6):348.[doi:10.3760/cma.j.issn.1673-4114.2012.06.007]
　LI Peng,ZHAO Wei-wei,YANG Jian-wei.18F-FDG PET-CT imaging in the detection of recurrent and metastasis ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):348.[doi:10.3760/cma.j.issn.1673-4114.2012.06.007]
[4]薛艳,安瑞芳.放射免疫显像在妇科肿瘤中的研究与应用[J].国际放射医学核医学杂志,2006,30(1):36.
　XUE Yan,AN Rui-fang.A research on radioimmunoimaging and its application in diagnosis of gynecological tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):36.
[5]史文琴.PET显像在卵巢癌诊断中的作用[J].国际放射医学核医学杂志,2001,25(4):158.
　SHI Wen-qin.The application of 18F-FDG PET in diagnosing of ovarian carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(3):158.
[6]张伟,于丽娟.18F-FDG PET/CT与18F-FDG PET/MRI在卵巢癌临床应用中的进展[J].国际放射医学核医学杂志,2018,(5):441.[doi:10.3760/cma.j.issn.1673-4114.2018.05.010]
　Zhang Wei,Yu Lijuan.Advances in clinical application of 18F-FDG PET/CT and 18F-FDG PET/MRI in ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(3):441.[doi:10.3760/cma.j.issn.1673-4114.2018.05.010]

备注/Memo

备注/Memo:
收稿日期:2016-02-26
基金项目:2013年天津市科技支撑计划重点项目(13ZCZDSY01000)
通讯作者:王立凯,Email:research@union-med.com
更新日期/Last Update: 1900-01-01